EP4076398
LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-PEF)
Status:
EP einkaleyfi: EP einkaleyfi tilnefnt til gildistöku á ÍslandiEP appl. date:
15.12.2020EP published:
18.2.2026EP application number:
20900848.1
EPO information:
European Patent Register
Max expiry date:
14.12.2040Expiry date:
14.12.2026
Title in English:
LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-PEF)Language of the patent:
English
Timeline
Today
15.12.2020EP application
18.2.2026EP Publication
14.12.2026Expires
Owner
Name:
Tenax Therapeutics, Inc.Address:
One Copley Parkway, Suite 490, Morrisville, NC 27560, US
Inventor
Name:
RANDALL, DouglasAddress:
Morrisville, NC 27560, US
Name:
HAY, DouglasAddress:
Ottsville, PA 18942, US
Name:
RICH, StuartAddress:
Skokie, IL 60076, US
Priority
Number:
201962948735 PDate:
16.12.2019Country:
US
Number:
202062967920 PDate:
30.1.2020Country:
US
Number:
202062988720 PDate:
12.3.2020Country:
US
Number:
202063033773 PDate:
2.6.2020Country:
US
Number:
202063064671 PDate:
12.8.2020Country:
US
Classification
Categories:
A61K 31/216, A61K 9/08, A61K 31/41, A61K 31/495, A61K 31/50, A61P 9/04, A61P 9/12, A61K 9/00